Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

S Dejager

Showing results (31-40 of 49) with videos related to

Pageof 5
Sort By:
Diabetes, Obesity & Metabolism|December 1, 2010
Clinical experience with vildagliptin in the management of type 2 diabetes in a patient population ≥75 years: a pooled analysis from a database of clinical trialsA Schweizer, S Dejager, J E Foley, et al.
Diabetes, Obesity & Metabolism|February 16, 2007
Vildagliptin in combination with pioglitazone improves glycaemic control in patients with type 2 diabetes failing thiazolidinedione monotherapy: a randomized, placebo-controlled studyA J Garber, A Schweizer, M A Baron, et al.
Diabetologia|March 28, 2007
Addition of vildagliptin to insulin improves glycaemic control in type 2 diabetesV Fonseca, A Schweizer, D Albrecht, et al.
Diabetes, Obesity & Metabolism|June 4, 2010
Assessing the cardio-cerebrovascular safety of vildagliptin: meta-analysis of adjudicated events from a large Phase III type 2 diabetes populationA Schweizer, S Dejager, J E Foley, et al.
Clinical Endocrinology|April 25, 2001
Smaller LDL particle size in women with polycystic ovary syndrome compared to controlsS Dejager, C Pichard, P Giral, et al.
Diabetes, Obesity & Metabolism|April 22, 2011
Mechanisms of action of the dipeptidyl peptidase-4 inhibitor vildagliptin in humansB Ahrén, A Schweizer, S Dejager, et al.
Diabetes Research and Clinical Practice|June 21, 2016
Which oral antidiabetic drug to combine with metformin to minimize the risk of hypoglycemia when initiating basal insulin?: A randomized controlled trial of a DPP4 inhibitor versus insulin secretagoguesJ F Gautier, P Monguillon, O Verier-Mine, et al.
Food and Chemical Toxicology : an International Journal Published for the British Industrial Biological Research Association|July 30, 2013
An investigational report into the causes of pine mouth events in US consumersErnest E Kwegyir-Afful, Lowri S Dejager, Sara M Handy, et al.
Food Additives & Contaminants. Part A, Chemistry, Analysis, Control, Exposure & Risk Assessment|March 18, 2022
Extraction and analysis of an organophosphate salt nucleating agent from irradiated polypropylene resinMary Dawn Celiz, Kim M Morehouse, Clark D Ridge, et al.
Diabetes, Obesity & Metabolism|January 8, 2009
Fifty-two-week efficacy and safety of vildagliptin vs. glimepiride in patients with type 2 diabetes mellitus inadequately controlled on metformin monotherapyE Ferrannini, V Fonseca, B Zinman, et al.
Pageof 5

Showing results (31-40 of 49) with videos related to

Sort By:
Pageof 5
Diabetes, Obesity & Metabolism|December 1, 2010
Clinical experience with vildagliptin in the management of type 2 diabetes in a patient population ≥75 years: a pooled analysis from a database of clinical trialsA Schweizer, S Dejager, J E Foley, et al.
Diabetes, Obesity & Metabolism|February 16, 2007
Vildagliptin in combination with pioglitazone improves glycaemic control in patients with type 2 diabetes failing thiazolidinedione monotherapy: a randomized, placebo-controlled studyA J Garber, A Schweizer, M A Baron, et al.
Diabetologia|March 28, 2007
Addition of vildagliptin to insulin improves glycaemic control in type 2 diabetesV Fonseca, A Schweizer, D Albrecht, et al.
Diabetes, Obesity & Metabolism|June 4, 2010
Assessing the cardio-cerebrovascular safety of vildagliptin: meta-analysis of adjudicated events from a large Phase III type 2 diabetes populationA Schweizer, S Dejager, J E Foley, et al.
Clinical Endocrinology|April 25, 2001
Smaller LDL particle size in women with polycystic ovary syndrome compared to controlsS Dejager, C Pichard, P Giral, et al.
Diabetes, Obesity & Metabolism|April 22, 2011
Mechanisms of action of the dipeptidyl peptidase-4 inhibitor vildagliptin in humansB Ahrén, A Schweizer, S Dejager, et al.
Diabetes Research and Clinical Practice|June 21, 2016
Which oral antidiabetic drug to combine with metformin to minimize the risk of hypoglycemia when initiating basal insulin?: A randomized controlled trial of a DPP4 inhibitor versus insulin secretagoguesJ F Gautier, P Monguillon, O Verier-Mine, et al.
Food and Chemical Toxicology : an International Journal Published for the British Industrial Biological Research Association|July 30, 2013
An investigational report into the causes of pine mouth events in US consumersErnest E Kwegyir-Afful, Lowri S Dejager, Sara M Handy, et al.
Food Additives & Contaminants. Part A, Chemistry, Analysis, Control, Exposure & Risk Assessment|March 18, 2022
Extraction and analysis of an organophosphate salt nucleating agent from irradiated polypropylene resinMary Dawn Celiz, Kim M Morehouse, Clark D Ridge, et al.
Diabetes, Obesity & Metabolism|January 8, 2009
Fifty-two-week efficacy and safety of vildagliptin vs. glimepiride in patients with type 2 diabetes mellitus inadequately controlled on metformin monotherapyE Ferrannini, V Fonseca, B Zinman, et al.
Pageof 5